• 1. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 2. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

Introduction to 3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic Acid (CAS No. 1261931-89-8)

3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic acid, identified by its CAS number 1261931-89-8, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical research and development. This compound belongs to the class of benzoic acids, which are widely recognized for their diverse biological activities and potential therapeutic applications. The structural features of this molecule, particularly the presence of a 4-methoxy-2-methylphenyl substituent and a 5-trifluoromethyl group, contribute to its unique chemical properties and make it a valuable scaffold for further chemical modifications and biological evaluations.

The benzoic acid moiety is a well-documented pharmacophore in medicinal chemistry, often serving as a core structure in the design of drugs targeting various diseases. The introduction of fluorine atoms, as seen in the 5-trifluoromethyl group, is a common strategy to enhance the metabolic stability and binding affinity of drug candidates. Additionally, the 4-methoxy-2-methylphenyl substituent introduces additional electronic and steric effects that can influence the compound's interactions with biological targets. These structural elements make 3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic acid a promising candidate for further investigation in drug discovery.

In recent years, there has been a growing interest in developing novel therapeutic agents with improved efficacy and reduced side effects. The compound 3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic acid has been explored in several preclinical studies for its potential applications in treating inflammatory diseases, cancer, and other metabolic disorders. The methoxy and methyl groups on the aromatic ring are known to modulate the pharmacokinetic properties of benzoic acid derivatives, enhancing their bioavailability and target specificity. Furthermore, the trifluoromethyl group contributes to the lipophilicity of the molecule, which is often crucial for crossing biological membranes and achieving effective drug delivery.

One of the most compelling aspects of 3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic acid is its versatility as a building block for more complex molecules. Researchers have utilized this compound as a precursor in synthesizing novel analogs with enhanced biological activity. For instance, modifications at the carboxylic acid group have led to derivatives with improved solubility and binding affinity to specific enzymes and receptors. These findings highlight the importance of this compound in medicinal chemistry and its potential to contribute to the development of next-generation therapeutics.

The synthesis of 3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic acid involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include Friedel-Crafts alkylation followed by halogenation and subsequent functional group transformations. Advanced techniques such as palladium-catalyzed cross-coupling reactions have also been employed to introduce additional substituents with high precision. These synthetic strategies underscore the compound's significance in industrial-scale production and its suitability for large-scale drug development programs.

The biological evaluation of 3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic acid has revealed several interesting properties that make it a compelling candidate for therapeutic applications. In vitro studies have demonstrated its ability to inhibit certain enzymes involved in inflammatory pathways, suggesting potential use in treating conditions such as rheumatoid arthritis and inflammatory bowel disease. Additionally, preliminary animal models have shown promising results in reducing tumor growth and metastasis, indicating its potential as an anti-cancer agent. These findings are particularly exciting given the increasing demand for targeted therapies that can modulate specific disease pathways without causing systemic side effects.

The safety profile of 3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic acid is another critical aspect that has been thoroughly investigated. Preclinical toxicology studies have assessed its acute toxicity, chronic exposure effects, and potential interactions with other drugs. The results from these studies indicate that the compound is well-tolerated at relevant therapeutic doses, with minimal evidence of organ toxicity or carcinogenicity. This favorable safety profile enhances its attractiveness as a lead compound for further clinical development.

The future directions for research on 3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic acid are multifaceted. One area of focus is optimizing its pharmacokinetic properties through structural modifications to improve bioavailability and reduce metabolism by first-pass effects. Another avenue involves exploring its potential as an inhibitor or activator of specific signaling pathways relevant to neurological disorders such as Alzheimer's disease and Parkinson's disease. Furthermore, collaborations between academic institutions and pharmaceutical companies are likely to accelerate the translation of preclinical findings into clinical trials, bringing this promising compound closer to market approval.

In conclusion, 3-(4-Methoxy-2-methylphenyl)-5-trifluoromethylbenzoic acid (CAS No. 1261931-89-8) is a structurally unique benzoic acid derivative with significant potential in pharmaceutical research. Its combination of electronic and steric features makes it an excellent scaffold for developing novel therapeutics targeting various diseases. The encouraging results from preclinical studies highlight its promise as a lead compound for further development, while ongoing research continues to uncover new applications and optimize its properties for clinical use.

• 926238-79-1(5-methoxy-2-[3-(trifluoromethyl)phenyl]benzoic Acid)
• 1261902-93-5(3-(4-Methoxyphenyl)-5-trifluoromethylbenzoic acid)
• 1261948-48-4(3-(3-Methoxyphenyl)-5-trifluoromethylbenzoic acid)
• 53985-48-1(3-Methoxy-5-(trifluoromethyl)benzoic acid)
• 1261481-51-9(5-Methoxy-3-(4-trifluoromethylphenyl)benzoic acid)
• 1261773-34-5(5-Methoxy-3'-(trifluoromethyl)biphenyl-3-carboxylic acid)
• 1261789-34-7(5-methoxy-2-[2-(trifluoromethyl)phenyl]benzoic Acid)
• 1261907-60-1(3-(3-Ethoxyphenyl)-5-trifluoromethylbenzoic acid)
• 1261565-92-7(5-Methoxy-2'-(trifluoromethyl)biphenyl-3-carboxylic acid)
• 1262006-62-1(4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic acid)